QIAGEN (QGEN)
(Delayed Data from NYSE)
$44.90 USD
-0.69 (-1.51%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $44.91 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
QGEN 44.90 -0.69(-1.51%)
Will QGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QGEN
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
QGEN Stock Likely to Gain From Innovation Amid Competition
QGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
Other News for QGEN
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
Qiagen launches 100 new assays for its digital PCR to study cancer
IN BRIEF: Qiagen extends collaboration on blood screening in Brazil
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil?s national screening programs
Qiagen and Bio-Manguinhos/Fiocruz collaborate to enhance malaria screening